{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:39:01Z","timestamp":1781660341830,"version":"3.54.5"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The recombinant ALVAC vaccine coupled with the monomeric gp120\/alum protein have decreased the risk of HIV and SIV acquisition. Ab responses to the V1\/V2 regions have correlated with a decreased risk of virus acquisition in both humans and macaques. We hypothesized that the breadth and functional profile of Abs induced by an ALVAC\/envelope protein regimen could be improved by substituting the monomeric gp120 boost, with the full-length single-chain (FLSC) protein. FLSC is a CD4-gp120 fusion immunogen that exposes cryptic gp120 epitopes to the immune system. We compared the immunogenicity and relative efficiency of an ALVAC-SIV vaccine boosted either with bivalent FLSC proteins or with monomeric gp120 in alum. FLSC was superior to monomeric gp120 in directing Abs to the C3 \u03b12 helix, the V5 loop, and the V3 region that contains the putative CCR5 binding site. In addition, FLSC boosting elicited significantly higher binding Abs to V2 and increased both the Ab-dependent cellular cytotoxicity activity and the breadth of neutralizing Abs. However, the FLSC vaccine regimen demonstrated only a trend in vaccine efficacy, whereas the monomeric gp120 regimen significantly decreased the risk of SIVmac251 acquisition. In both vaccine regimens, anti-V2 Abs correlated with a decreased risk of virus acquisition but differed with regard to systemic or mucosal origin. In the FLSC regimen, serum Abs to V2 correlated, whereas in the monomeric gp120 regimen, V2 Abs in rectal secretions, the site of viral challenge, were associated with efficacy.<\/jats:p>","DOI":"10.4049\/jimmunol.1600674","type":"journal-article","created":{"date-parts":[[2016,9,3]],"date-time":"2016-09-03T02:28:15Z","timestamp":1472869695000},"page":"2726-2737","source":"Crossref","is-referenced-by-count":32,"title":["Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition"],"prefix":"10.1093","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6715-7334","authenticated-orcid":false,"given":"Shari N","family":"Gordon","sequence":"first","affiliation":[{"name":"Animal Models and Vaccine Section, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7362-3282","authenticated-orcid":false,"given":"Namal P M","family":"Liyanage","sequence":"additional","affiliation":[{"name":"Animal Models and Vaccine Section, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin N","family":"Doster","sequence":"additional","affiliation":[{"name":"Animal Models and Vaccine Section, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Vaccari","sequence":"additional","affiliation":[{"name":"Animal Models and Vaccine Section, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7405-9572","authenticated-orcid":false,"given":"Diego A","family":"Vargas-Inchaustegui","sequence":"additional","affiliation":[{"name":"Immune Biology of Retroviral Infection Section, Vaccine Branch, National Cancer Institute , Bethesda, MD 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7926-3118","authenticated-orcid":false,"given":"Poonam","family":"Pegu","sequence":"additional","affiliation":[{"name":"Animal Models and Vaccine Section, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Schifanella","sequence":"additional","affiliation":[{"name":"Animal Models and Vaccine Section, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Shen","sequence":"additional","affiliation":[{"name":"Duke University Medical Center , Durham, NC 27710"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8076-1931","authenticated-orcid":false,"given":"Georgia D","family":"Tomaras","sequence":"additional","affiliation":[{"name":"Duke University Medical Center , Durham, NC 27710"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9553-4969","authenticated-orcid":false,"given":"Mangala","family":"Rao","sequence":"additional","affiliation":[{"name":"U.S. Military HIV Research Program, Walter Reed Army Institute of Research , Silver Spring, MD 20910"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8963-0484","authenticated-orcid":false,"given":"Erik A","family":"Billings","sequence":"additional","affiliation":[{"name":"U.S. Military HIV Research Program, Walter Reed Army Institute of Research , Silver Spring, MD 20910"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8239-8857","authenticated-orcid":false,"given":"Jennifer","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Profectus BioSciences Inc. , Baltimore, MD 21224"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilia","family":"Prado","sequence":"additional","affiliation":[{"name":"Profectus BioSciences Inc. , Baltimore, MD 21224"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Bobb","sequence":"additional","affiliation":[{"name":"Profectus BioSciences Inc. , Baltimore, MD 21224"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Profectus BioSciences Inc. , Baltimore, MD 21224"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0856-6319","authenticated-orcid":false,"given":"David C","family":"Montefiori","sequence":"additional","affiliation":[{"name":"Duke University Medical Center , Durham, NC 27710"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E","family":"Foulds","sequence":"additional","affiliation":[{"name":"Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MD 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7747-3349","authenticated-orcid":false,"given":"Guido","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Duke University Medical Center , Durham, NC 27710"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie","family":"Robert-Guroff","sequence":"additional","affiliation":[{"name":"Immune Biology of Retroviral Infection Section, Vaccine Branch, National Cancer Institute , Bethesda, MD 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7448-7040","authenticated-orcid":false,"given":"Mario","family":"Roederer","sequence":"additional","affiliation":[{"name":"Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MD 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tran B","family":"Phan","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of California, Irvine School of Medicine , Irvine, CA 92868"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald N","family":"Forthal","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of California, Irvine School of Medicine , Irvine, CA 92868"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald M","family":"Stablein","sequence":"additional","affiliation":[{"name":"The Emmes Corporation , Rockville, MD 20850"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Phogat","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur , Swiftwater, PA 18370"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8990-158X","authenticated-orcid":false,"given":"David J","family":"Venzon","sequence":"additional","affiliation":[{"name":"Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2429-2859","authenticated-orcid":false,"given":"Timothy","family":"Fouts","sequence":"additional","affiliation":[{"name":"Profectus BioSciences Inc. , Baltimore, MD 21224"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5171-9849","authenticated-orcid":false,"given":"Genoveffa","family":"Franchini","sequence":"additional","affiliation":[{"name":"Animal Models and Vaccine Section, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,10,1]]},"reference":[{"key":"2025030617521777500_r1","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"2025030617521777500_r2","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"2025030617521777500_r3","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1128\/JVI.01023-12","article-title":"Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family","volume":"86","author":"Bonsignori","year":"2012","journal-title":"J. Virol."},{"key":"2025030617521777500_r4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/72318","article-title":"Protection of macaques against vaginal transmission of a pathogenic HIV-1\/SIV chimeric virus by passive infusion of neutralizing antibodies","volume":"6","author":"Mascola","year":"2000","journal-title":"Nat. Med."},{"key":"2025030617521777500_r5","doi-asserted-by":"crossref","first-page":"18921","DOI":"10.1073\/pnas.1214785109","article-title":"Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo","volume":"109","author":"Moldt","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030617521777500_r6","doi-asserted-by":"crossref","first-page":"11181","DOI":"10.1073\/pnas.1103012108","article-title":"Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody","volume":"108","author":"Burton","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030617521777500_r7","doi-asserted-by":"crossref","first-page":"e1002890","DOI":"10.1371\/journal.ppat.1002890","article-title":"ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge","volume":"8","author":"Alpert","year":"2012","journal-title":"PLoS Pathog."},{"key":"2025030617521777500_r8","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1128\/JVI.06812-11","article-title":"Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge","volume":"86","author":"Xiao","year":"2012","journal-title":"J. Virol."},{"key":"2025030617521777500_r9","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.4049\/jimmunol.157.5.2168","article-title":"HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression","volume":"157","author":"Baum","year":"1996","journal-title":"J. Immunol."},{"key":"2025030617521777500_r10","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1086\/314988","article-title":"Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients","volume":"180","author":"Forthal","year":"1999","journal-title":"J. Infect. Dis."},{"key":"2025030617521777500_r11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2174\/1570162X113116660063","article-title":"Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention","volume":"11","author":"Vargas-Inchaustegui","year":"2013","journal-title":"Curr. HIV Res."},{"key":"2025030617521777500_r12","doi-asserted-by":"crossref","first-page":"e1002739","DOI":"10.1371\/journal.ppat.1002739","article-title":"HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads","volume":"8","author":"Mabuka","year":"2012","journal-title":"PLoS Pathog."},{"key":"2025030617521777500_r13","doi-asserted-by":"crossref","first-page":"6596","DOI":"10.4049\/jimmunol.178.10.6596","article-title":"Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate","volume":"178","author":"Forthal","year":"2007","journal-title":"J. Immunol."},{"key":"2025030617521777500_r14","doi-asserted-by":"crossref","first-page":"e1005042","DOI":"10.1371\/journal.ppat.1005042","article-title":"Human non-neutralizing HIV-1 envelope monoclonal antibodies limit the number of founder viruses during SHIV mucosal infection in rhesus macaques","volume":"11","author":"Santra","year":"2015","journal-title":"PLoS Pathog."},{"key":"2025030617521777500_r15","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1126\/science.280.5371.1884","article-title":"The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens","volume":"280","author":"Wyatt","year":"1998","journal-title":"Science"},{"key":"2025030617521777500_r16","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1126\/science.280.5371.1949","article-title":"A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding","volume":"280","author":"Rizzuto","year":"1998","journal-title":"Science"},{"key":"2025030617521777500_r17","doi-asserted-by":"crossref","first-page":"E69","DOI":"10.1073\/pnas.1217609110","article-title":"Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding","volume":"110","author":"Guan","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030617521777500_r18","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.1128\/JVI.00171-11","article-title":"An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum","volume":"85","author":"Ferrari","year":"2011","journal-title":"J. Virol."},{"key":"2025030617521777500_r19","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1128\/JVI.03230-13","article-title":"Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity","volume":"88","author":"Veillette","year":"2014","journal-title":"J. Virol."},{"key":"2025030617521777500_r20","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1089\/08892220260387959","article-title":"Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies","volume":"18","author":"Xiang","year":"2002","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"2025030617521777500_r21","doi-asserted-by":"crossref","first-page":"11427","DOI":"10.1128\/JVI.74.24.11427-11436.2000","article-title":"Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex","volume":"74","author":"Fouts","year":"2000","journal-title":"J. Virol."},{"key":"2025030617521777500_r22","doi-asserted-by":"crossref","first-page":"17477","DOI":"10.1073\/pnas.0707399104","article-title":"Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens","volume":"104","author":"DeVico","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030617521777500_r23","doi-asserted-by":"crossref","first-page":"E992","DOI":"10.1073\/pnas.1423669112","article-title":"Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection","volume":"112","author":"Fouts","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030617521777500_r24","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm.4105","article-title":"Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition","volume":"22","author":"Vaccari","year":"2016","journal-title":"Nat. Med."},{"key":"2025030617521777500_r25","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1128\/JVI.03507-12","article-title":"Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies","volume":"87","author":"Del Prete","year":"2013","journal-title":"J. Virol."},{"key":"2025030617521777500_r26","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1084\/jem.20082831","article-title":"Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1","volume":"206","author":"Keele","year":"2009","journal-title":"J. Exp. Med."},{"key":"2025030617521777500_r27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/08820139709048912","article-title":"NASBA technology: isothermal RNA amplification in qualitative and quantitative diagnostics","volume":"26","author":"Romano","year":"1997","journal-title":"Immunol. Invest."},{"key":"2025030617521777500_r28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jviromet.2009.10.012","article-title":"Molecular methods for evaluation of virological status of nonhuman primates challenged with simian immunodeficiency or simian-human immunodeficiency viruses","volume":"163","author":"Lee","year":"2010","journal-title":"J. Virol. Methods"},{"key":"2025030617521777500_r29","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1128\/JVI.02863-12","article-title":"Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure","volume":"87","author":"Vaccari","year":"2013","journal-title":"J. Virol."},{"key":"2025030617521777500_r30","article-title":"Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays","volume-title":"Curr. Protoc. Immunol.","author":"Montefiori","year":"2005"},{"key":"2025030617521777500_r31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jim.2005.09.018","article-title":"A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity","volume":"308","author":"G\u00f3mez-Rom\u00e1n","year":"2006","journal-title":"J. Immunol. Methods"},{"key":"2025030617521777500_r32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jim.2012.07.006","article-title":"Role of monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity","volume":"384","author":"Kramski","year":"2012","journal-title":"J. Immunol. Methods"},{"key":"2025030617521777500_r33","doi-asserted-by":"crossref","first-page":"12449","DOI":"10.1128\/JVI.01708-08","article-title":"Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia","volume":"82","author":"Tomaras","year":"2008","journal-title":"J. Virol."},{"key":"2025030617521777500_r34","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nature12893","article-title":"Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV","volume":"505","author":"Roederer","year":"2014","journal-title":"Nature"},{"key":"2025030617521777500_r35","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1128\/JVI.02544-12","article-title":"Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial","volume":"87","author":"Pegu","year":"2013","journal-title":"J. Virol."},{"key":"2025030617521777500_r36","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1182\/blood.V87.8.3450.bloodjournal8783450","article-title":"Neutrophil deactivation by influenza A viruses: mechanisms of protection after viral opsonization with collectins and hemagglutination-inhibiting antibodies","volume":"87","author":"Hartshorn","year":"1996","journal-title":"Blood"},{"key":"2025030617521777500_r37"},{"key":"2025030617521777500_r38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jim.2010.12.016","article-title":"A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples","volume":"366","author":"Ackerman","year":"2011","journal-title":"J. Immunol. Methods"},{"key":"2025030617521777500_r39","doi-asserted-by":"crossref","first-page":"e75665","DOI":"10.1371\/journal.pone.0075665","article-title":"Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial","volume":"8","author":"Gottardo","year":"2013","journal-title":"PLoS One"},{"key":"2025030617521777500_r40","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/384184a0","article-title":"CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5","volume":"384","author":"Trkola","year":"1996","journal-title":"Nature"},{"key":"2025030617521777500_r41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/384179a0","article-title":"CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5","volume":"384","author":"Wu","year":"1996","journal-title":"Nature"},{"key":"2025030617521777500_r42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1126\/science.1905842","article-title":"Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1","volume":"253","author":"Hwang","year":"1991","journal-title":"Science"},{"key":"2025030617521777500_r43","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1128\/JVI.78.7.3223-3232.2004","article-title":"Amino acid 324 in the simian immunodeficiency virus SIVmac V3 loop can confer CD4 independence and modulate the interaction with CCR5 and alternative coreceptors","volume":"78","author":"P\u00f6hlmann","year":"2004","journal-title":"J. Virol."},{"key":"2025030617521777500_r44","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1126\/science.1118398","article-title":"Structure of a V3-containing HIV-1 gp120 core","volume":"310","author":"Huang","year":"2005","journal-title":"Science"},{"key":"2025030617521777500_r45","doi-asserted-by":"crossref","first-page":"9911","DOI":"10.1128\/JVI.00533-09","article-title":"Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4","volume":"83","author":"Del Prete","year":"2009","journal-title":"J. Virol."},{"key":"2025030617521777500_r46","doi-asserted-by":"crossref","first-page":"e87572","DOI":"10.1371\/journal.pone.0087572","article-title":"Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection","volume":"9","author":"Zolla-Pazner","year":"2014","journal-title":"PLoS One"},{"key":"2025030617521777500_r47","doi-asserted-by":"crossref","first-page":"e53629","DOI":"10.1371\/journal.pone.0053629","article-title":"Analysis of V2 antibody responses induced in vaccinees in the ALVAC\/AIDSVAX HIV-1 vaccine efficacy trial","volume":"8","author":"Zolla-Pazner","year":"2013","journal-title":"PLoS One"},{"key":"2025030617521777500_r48","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00126334-200502010-00002","article-title":"Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV","volume":"38","author":"Van Rompay","year":"2005","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"2025030617521777500_r49","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1016\/j.vaccine.2012.04.082","article-title":"A trivalent recombinant Ad5 gag\/pol\/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge","volume":"30","author":"Reynolds","year":"2012","journal-title":"Vaccine"},{"key":"2025030617521777500_r50","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1128\/JVI.06175-11","article-title":"Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag\/pol\/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine","volume":"86","author":"Qureshi","year":"2012","journal-title":"J. Virol."},{"key":"2025030617521777500_r51","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature11519","article-title":"Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2","volume":"490","author":"Rolland","year":"2012","journal-title":"Nature"},{"key":"2025030617521777500_r52","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1128\/JVI.03419-12","article-title":"Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock","volume":"87","author":"Lopker","year":"2013","journal-title":"J. Virol."},{"key":"2025030617521777500_r53","doi-asserted-by":"crossref","first-page":"e1000598","DOI":"10.1371\/journal.ppat.1000598","article-title":"Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection","volume":"5","author":"Moore","year":"2009","journal-title":"PLoS Pathog."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/197\/7\/2726\/61580961\/1600674.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/197\/7\/2726\/61580961\/1600674.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T19:07:53Z","timestamp":1741288073000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/197\/7\/2726\/7974644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,1]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,10,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1600674","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,10]]},"published":{"date-parts":[[2016,10,1]]}}}